Clinical Trials
5
Active:0
Completed:0
Trial Phases
2 Phases
Phase 2:4
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 2
4 (80.0%)Phase 3
1 (20.0%)An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as Maintenance Therapy in Chinese
Phase 2
- Conditions
- Small Cell Lung CancerDurvalumabLung Cancer
- Interventions
- First Posted Date
- 2022-02-18
- Last Posted Date
- 2022-02-18
- Lead Sponsor
- Li Zhang, MD
- Target Recruit Count
- 60
- Registration Number
- NCT05245994
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Ensatinib Treat Second-generation ALK-TKI Resistance After Second-generation ALK-TKI Resistance
Phase 2
Recruiting
- Conditions
- Second Generation ALK-TKI is ResistantThe Diagnosis Was ALK Positive NSCLCEfficacy of Ensatinib in This Subset of Patients
- Interventions
- First Posted Date
- 2022-01-05
- Last Posted Date
- 2022-01-05
- Lead Sponsor
- Li Zhang, MD
- Target Recruit Count
- 40
- Registration Number
- NCT05178511
- Locations
- 🇨🇳
Sun Yat-sen University, Guangzhou, Guangdong, China
Surufatinib Combined With Toripalimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer
Phase 2
Recruiting
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Drug: Surufatinib,Toripalimab,Pemetrexed,Carboplatin/Cisplatin
- First Posted Date
- 2021-08-12
- Last Posted Date
- 2022-11-04
- Lead Sponsor
- Li Zhang, MD
- Target Recruit Count
- 106
- Registration Number
- NCT05003037
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guang Dong, China
Phase III Study Comparing Osimertinib Monotherapy to Combination Therapy With Osimertinib,Carboplatin and Pemetrexed for Untreated Patients With Advanced Non-squamous Non-Small Cell Lung Cancer With Concurrent EGFR and TP53 Mutations
Phase 3
- Conditions
- Non-small Cell CarcinomaEGFR Gene Mutation
- Interventions
- First Posted Date
- 2021-01-05
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Li Zhang, MD
- Target Recruit Count
- 291
- Registration Number
- NCT04695925
- Locations
- 🇨🇳
Department of Medical Oncology,Cancer Center of Sun Yat-Sen University, Guangzhou, Guangdong, China
JS001 Combination Therapy in NSCLC Negative Driving Gene After First-line Chemotherapy.
Phase 2
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2020-07-07
- Lead Sponsor
- Li Zhang, MD
- Target Recruit Count
- 50
- Registration Number
- NCT04459663
- Locations
- 🇨🇳
Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China
News
No news found